证券日报网讯8月18日晚间，昂利康（002940）发布公告称，公司不存在逾期担保的情况，不存在对控 股股东和实际控制人及其关联人提供担保的情况，不存在涉及诉讼的担保，亦不存在因担保事项被判决 败诉而应承担损失的情况。 ...

特别提示： 证券代码：002940 证券简称：昂利康 公告编号：2025-059 浙江昂利康制药股份有限公司 关于为控股子公司向银行申请授信提供担保进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本次担保事项系公司拟为合并报表范围内控股子公司浙江昂利康动保科技 有限公司（以下简称"动保科技"）向商业银行申请授信提供担保，公司为动保 科技提供 1,040 万元连带责任担保，本次被担保对象动保科技资产负债率超过 70%。 浙江昂利康制药股份有限公司（以下简称"公司"或"昂利康"）分别于 2025 年 4 月 24 日、2025 年 5 月 16 日召开第四届董事会第七次会议、2024 年度股东 大会，审议通过了《关于为控股子公司向银行申请授信提供担保的议案》，同意 公司为合并报表范围内控股子公司动保科技提供不超过 2,600 万元（含本数）连 带责任担保，授权担保额度有效期自 2024 年度股东大会审议通过之日起至 2025 年度股东大会召开之日止。在授权额度内的具体担保金额及担保期间按具体合同 约定执行。具体内容详见公司于 2025 年 4 月 26 ...

风险提示：股市有风险，投资需谨慎。 消息面上，8月13日盘中，昂利康曾出现快速反弹，5分钟内涨幅超过2%，股价一度拉升至53.5元，成 交额达4.22亿元。 资金流向方面，8月13日主力资金净流出6087.54万元，占流通市值的0.63%。近五个交易日累计净流出 2.00亿元，占流通市值的2.06%。 截至2025年8月13日收盘，昂利康股价报52.55元，较前一交易日下跌0.48元，跌幅0.91%。盘中股价波 动明显，最高触及54.00元，最低下探至51.50元，振幅达4.71%，全天成交额7.70亿元，换手率7.91%。 昂利康属于化学制药板块，业务涵盖原料药、制剂及医药中间体的研发、生产和销售。公司产品涉及抗 感染、心血管、消化系统等多个治疗领域，并在合成生物、创新药等方向有所布局。 ...

Core Viewpoint - The stock of Anglikon experienced a significant decline of 7.79% on the trading day, with a turnover rate of 8.55% and a total transaction value of 855 million yuan, indicating notable market activity and volatility [2]. Trading Activity - The stock was listed on the Shenzhen Stock Exchange's watch list due to a daily price deviation of -8.12%, with institutional investors net selling 93.29 million yuan [2]. - The top five trading departments accounted for a total transaction value of 223 million yuan, with a buying amount of 81.71 million yuan and a selling amount of 141 million yuan, resulting in a net sell of 59.79 million yuan [2]. - Among the trading departments, four institutional special seats were involved, with a total buying amount of 2.44 million yuan and a selling amount of 95.73 million yuan, leading to a net sell of 93.29 million yuan [2]. Fund Flow - The stock saw a net outflow of 79.81 million yuan in principal funds, with large orders contributing to a net outflow of 42.80 million yuan and a net outflow of 37.02 million yuan from big orders [2]. - Over the past five days, the stock has experienced a total net outflow of 113 million yuan [2]. Historical Performance - In the past six months, the stock has appeared on the watch list 13 times, with an average price increase of 2.32% the day after being listed and an average increase of 1.67% over the following five days [2].

昂利康今日跌7.79%，成交额8.55亿元，换手率8.55%，盘后龙虎榜数据显示，有4家机构专用席位净卖 出9329.13万元。 ...

证券之星消息，8月12日化学制药板块较上一交易日下跌0.75%，昂利康领跌。当日上证指数报收于 3665.92，上涨0.5%。深证成指报收于11351.63，上涨0.53%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300194 | 福安药业 | 5.02 | 7.73% | 200.78万 | | 10.38亿 | | 600513 | 联环药业 | 25.65 | 7.01% | 65.27万 | | 16.32亿 | | 300584 | 海辰约业 | 51.30 | 6.39% | 22.45万 | | 11.39 乙 | | 603669 | 灵康药业 | 6.05 | 6.14% | 66.66万 | | 3.98亿 | | 301075 | 多瑞医药 | 37.80 | 5.88% | 5.87万 | | 2.13亿 | | 301258 | 富士莱 | 39.02 | 4.22% | 7.16万 | | 2.75亿 | | 00 ...

Market Overview - The Shanghai Composite Index closed at 3653.50 points, with a change of +0.51% [1] - The total trading volume of A-shares reached 1,149.623 billion yuan [1] Technical Analysis - A total of 17 A-shares experienced a "death cross" where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Angli (002940) with a distance of -1.91% - Chengdu Xian Dao (688222) with a distance of -1.51% - Saiseng Pharmaceutical (300485) with a distance of -1.38% [1] Individual Stock Performance - Angli (002940) saw a daily increase of 2.02% with a turnover rate of 4.48% [1] - Chengdu Xian Dao (688222) increased by 1.47% with a turnover rate of 2.10% [1] - Saiseng Pharmaceutical (300485) experienced a slight decrease of -0.14% with a turnover rate of 3.10% [1] - Other stocks with notable performance include: - Jintai (688443) up by 1.78% - Changshan Pharmaceutical (300255) up by 2.29% - Zhizheng (603991) down by -1.69% [1]

Market Overview - The Shanghai Composite Index is at 3639.18 points with a change of 0.11% [1] - The total trading volume of A-shares is 832.786 billion yuan [1] Stocks with Death Cross - 20 A-shares have seen their 5-day moving average cross below the 10-day moving average [1] - Notable stocks include: - Angli (002940) with a 5-day moving average of 56.59 yuan, down 1.78% from the 10-day moving average [1] - Chengdu Xian Dao (688222) with a 5-day moving average of 23.11 yuan, down 1.64% [1] - Sai Sheng Pharmaceutical (300485) with a 5-day moving average of 14.83 yuan, down 1.40% [1] Additional Stock Data - Other stocks with significant moving average changes include: - Zhi Xiang (688443) with a 5-day moving average of 33.34 yuan, down 0.85% [1] - Changshan Pharmaceutical (300255) with a 5-day moving average of 41.59 yuan, down 0.68% [1] - Zhi Zheng (603991) with a 5-day moving average of 72.69 yuan, down 0.40% [1] Performance Summary - The performance of various stocks shows a mix of slight gains and losses, with some stocks like Angli and Chengdu Xian Dao experiencing notable declines in their moving averages [1][2] - The overall market sentiment appears cautious, reflected in the trading volumes and the number of stocks showing bearish signals [1]

Summary of the Conference Call Company and Industry Overview - The conference call discusses **昂立康 (Angli Kang)**, a company focused on the pharmaceutical industry, particularly in the development of innovative cancer therapies and traditional pharmaceutical products [2][14]. Key Points and Arguments - **TMEA Platform**: The company utilizes the TMEA platform for targeted drug delivery in the tumor microenvironment, which addresses systemic toxicity issues. The platform's effectiveness is validated by the clinical phase III results of **来谷比星 (Lai Gu Bi Xing)**, a lead drug that outperformed first-line chemotherapy [2][3][9]. - **N001 Development**: N001, an anti-tumor drug based on the TMEA platform, is currently in phase I clinical trials targeting advanced solid tumors. It aims to assess safety, tolerability, pharmacokinetics, and efficacy [2][4][7]. - **Financial Projections**: The company anticipates a net profit of **1.3 billion** yuan in 2025, representing a **64%** year-on-year increase. Revenue growth is projected at **18%**, **21%**, and **20%** for 2025, 2026, and 2027, respectively [2][10][24]. - **Market Expansion**: Angli Kang is actively expanding into international markets, including Taiwan, India, Brazil, Vietnam, and South Korea, to drive overall performance growth [4][17]. - **Innovation Focus**: The company is concentrating on innovative drug development, particularly in the area of reduced toxicity and enhanced efficacy chemotherapy products. The overall chemotherapy market exceeds **100 billion** yuan [3][10]. Additional Important Information - **Clinical Trial Results**: Lai Gu Bi Xing's phase III trial demonstrated significant efficacy and safety compared to existing first-line chemotherapy, with primary endpoints including progression-free survival and cardiac toxicity [11]. - **Product Pipeline**: The company has a diverse product pipeline, including small molecules and large molecules, aimed at addressing toxicity issues while improving therapeutic efficacy [12][13]. - **Traditional Drug Transformation**: Angli Kang is transitioning traditional formulations to injectable, compound, controlled-release, and transdermal patch formulations to enhance profitability [21]. - **Specialty Intermediates**: The specialty intermediates segment focuses on high-purity plant-derived cholesterol, with a projected net profit margin of **40%** in 2024, indicating a stable cash flow business [22]. - **Animal Health Sector**: The company is expanding its animal health division, particularly in anesthetics and anti-infection products, with a goal to double sales of its flagship product in 2025 [23]. Conclusion - Angli Kang is positioned for growth through innovative drug development, market expansion, and a focus on transforming traditional pharmaceutical products. The company's strategic initiatives and financial projections indicate a positive outlook for the coming years [10][24].

Group 1 - On August 8, the stock price of Anglikang closed at 54.34 yuan, down 1.41 yuan or 2.53% from the previous trading day [1] - The opening price on the same day was 55.64 yuan, with a highest point of 57.25 yuan and a lowest point of 54.06 yuan, with a trading volume of 140,753 hands and a transaction amount of 777 million yuan [1] - Around 10:12 AM on August 8, Anglikang's stock price experienced a rapid rebound, increasing over 2% within 5 minutes, rising from 55.59 yuan to 56.1 yuan, with a transaction amount of 199 million yuan during this period [1] Group 2 - Anglikang operates in the chemical pharmaceutical industry, focusing on the research, production, and sales of pharmaceutical products [1] - The company's product range includes treatments for various fields such as anti-infection, cardiovascular, and digestive systems [1] Group 3 - On August 8, the net outflow of main funds was 49.57 million yuan, with a cumulative net outflow of 296 million yuan over the past five trading days [1]